- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00409695
Thymoglobulin (ATG) Dose Finding Study
Dose Finding Study of Thymoglobulin (ATG) in Patients With Steroid-Refractory Acute Graft Versus Host Disease (aGVHD)
Primary Objective:
- To determine the response and toxicity rate at day 56 of two different dose levels of thymoglobulin (ATG) [anti-thymocyte globulin (rabbit)] as a treatment of steroid-refractory acute graft versus host disease (aGVHD).
Secondary Objectives:
- To evaluate the response rate at day 28.
- To evaluate the overall survival and non-relapse mortality at 6 months.
- To determine the toxicity profile of thymoglobulin when used for the treatment of steroid-refractory aGVHD in each of two dose schedules.
- To characterize the pharmacokinetic profile of thymoglobulin in each of two dose schedules.
- To analyze biomarkers of cellular drug effect by quantifying T-cell apoptosis in aims of finding the minimal effective dose.
- To determine immune-reconstitution after administration of thymoglobulin to patients with steroid-refractory aGVHD for each dose schedule.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
GvHD is a common side effect of a stem cell transplant. It is caused by a type of white blood cell (a lymphocyte). ATG is designed to kill lymphocytes and is commonly used to help prevent or treat GvHD and to treat steroid-refractory aGvHD.
Before you can start treatment on this study, you will have "screening tests." These tests will help the doctor decide if you are eligible to take part in this study. You will be asked questions about your medical history. You will have a complete physical exam. You will have blood drawn (about 2 tablespoons) for routine tests and to check for any viral infections. Women who are able to have children must have a negative blood (about 1 teaspoon) or urine pregnancy test. You will also have a biopsy of the site that is suspected to be affected by aGvHD. The study doctor will describe the type of biopsy procedure you will have, which will depend on the part of the body that is affected by the disease. If you had an earlier biopsy performed that confirmed aGvHD, you will not need a biopsy repeated for this study.
If you are found to be eligible to participate in this study, you will be randomly assigned (as in the toss of a coin) to 1 of 2 groups. Participants in Group 1 will receive a higher dose of ATG by vein. Participants in Group 2 will receive a lower dose of ATG by vein. You will have an equal chance of being in 1 of the 2 groups. Participants in both groups will receive doses of ATG over 4-6 hours, 1 time a day every other day for a total of 3 doses.
During this study, you will be able to remain on steroids and any other drugs you may be receiving for treatment of aGvHD (such as tacrolimus or cyclosporine). You will also have blood drawn (about 1 teaspoon) to learn the effect of ATG on the lymphocytes.
You will be taken off this study, if the disease is stable as determined by the study doctor, if the disease gets worse, or you experience any intolerable side effects. If you are taken off this study, your study doctor will discuss other treatment options with you.
After you finish receiving the study medication, you will come to the clinic at regularly scheduled follow-up visits. At first, you will be seen in the clinic once a week for 1 month. You will also have additional blood drawn (about 2 teaspoons) for biomarker testing (testing that looks at how the drug is working in your body). After the first month of follow-up visits, you will come in for visits every other week while you are on this study, which will continue until you have at least 2 consecutive (back to back) evaluations of the disease status to see if the disease is stable.
This is an investigational study. ATG is FDA approved and commercially available. You and/or your insurance provider will be financially responsible for the cost of ATG while you are on this study. Up to 40 patients will take part in this study. All will be enrolled at M.D. Anderson.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- U.T. M.D. Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who underwent their first allogeneic transplant for any malignancy and with any cell (bone marrow, peripheral stem cell, cord blood) or donor (matched or mismatched related or unrelated) source.
- Biopsy-proven, grade II-IV aGVHD following allogeneic hematopoietic stem cell transplantation (HSCT) of any source (bone marrow, peripheral blood or cord blood stem cells). Enrollment may be started prior to results of biopsy in cases of high clinical suspicion for aGVHD.
- Early steroid-refractory aGVHD. This is defined as any NR or PD after a minimum of 3 days and not more than 1 week of 1 mg/kg/day of methylprednisolone.
- Ability to sign informed consent.
- Ability to return for clinical follow-up as specified in the protocol.
- Inability to taper as defined by patients on < or = 1 mg/kg/day of methylprednisolone but unable to further taper without resultant increase of acute GVHD stage.
- Patients with a reflare of a GVHD defined as worsening of 1 stage of acute GVHD in a patient who initially responded.
Exclusion Criteria:
- Relapsed malignancy.
- Acute GVHD as a result of a second or subsequent transplant or donor lymphocyte infusion (DLI).
- Active, uncontrolled infection.
- Patients who have received any second-line of immunosuppressive treatment for GVHD beyond corticosteroids and calcineurin inhibitors. Topical steroids, oral budesonide and extracorporeal photochemotherapy started at the time of steroids are allowed.
- Life-threatening infusion reaction or hypersensitivity to any formulation of ATG in the past.
- Patients who are pregnant or are breast feeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: High Dose Thymoglobulin (ATG)
High Dose Thymoglobulin (ATG): 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
|
1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
Other Names:
|
EXPERIMENTAL: Low Dose Thymoglobulin (ATG)
Low Dose Thymoglobulin (ATG): 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
|
2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate
Time Frame: Day 56
|
Response assessed at day 56, and a complete response or partial response considered a success.
A toxic event defined as a life threatening infection, any death due to infection, or any death considered to be directly related to the administration of ATG.
|
Day 56
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Amin M. Alousi, MD, M.D. Anderson Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006-0370
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graft vs Host Disease
-
Dana-Farber Cancer InstituteBayer; Genzyme, a Sanofi CompanyCompleted
-
Rambam Health Care CampusWithdrawnFecal Microbiota Transplantation in Graft vs. Host DiseaseIsrael
-
Novartis PharmaceuticalsCompletedCorticosteroid Refractory Acute Graft vs Host DiseaseGermany, Japan, Saudi Arabia, Turkey, United Kingdom, Spain, Canada, Italy, Australia, Austria, France, Korea, Republic of, Hong Kong, Israel, Netherlands, Russian Federation, Denmark, Greece, Taiwan, Norway, Czechia, Bulgaria
-
Washington University School of MedicineCompletedGraft Vs Host Disease | Graft-versus-host-diseaseUnited States
-
Shenzhen University General HospitalRecruitingGraft Vs Host DiseaseChina
-
National Cancer Institute (NCI)TerminatedGraft vs Host Disease | Graft-Versus-Host Disease | Chronic Graft vs. Host DiseaseUnited States
-
Boston Children's HospitalBristol-Myers SquibbRecruitingGraft Vs Host DiseaseUnited States
-
Christopher DvorakRecruitingGraft Vs Host Disease | Graft-versus-host-diseaseUnited States
-
Fred Hutchinson Cancer CenterFacet BiotechUnknownGraft-vs-Host DiseaseUnited States
-
Rabin Medical CenterUnknownGraft Vs Host DiseaseIsrael
Clinical Trials on High Dose Thymoglobulin (ATG)
-
Shanghai General Hospital, Shanghai Jiao Tong University...UnknownLymphoblastic LymphomaChina
-
National Institute of Blood Disease Center, PakistanUnknown
-
University Hospital, LilleErasme University HospitalCompletedRenal TransplantationFrance
-
AtoGen Co. LtdATOGEN AUSTRALIA PTY LTDRecruitingBacterial Infections | Vaginal Disease | Vaginitis | Infection, Bacterial | Bacterial VaginosisAustralia
-
Shanghai General Hospital, Shanghai Jiao Tong University...The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsUnknownAcute Lymphoblastic Leukemia | Lymphoblastic LymphomaChina
-
University Hospital, Basel, SwitzerlandCompleted
-
Beijing Northland Biotech. Co., Ltd.CompletedAcute Myocardial InfarctionChina
-
National Institute of Diabetes and Digestive and...Washington University School of Medicine; University of Alabama at Birmingham; Icahn School of Medicine at Mount Sinai and other collaboratorsCompletedEnd Stage Renal DiseaseUnited States
-
Wang XinNot yet recruiting
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico